MD ANDERSON CANCER CENTER signed a three-year translational and clinical research agreement with MedImmune to develop anti-cancer immunotherapies through the center’s Moon Shots Program. MedImmune is the global biologics research and development arm of AstraZeneca.
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
